SEC Comment Letter for BIOMARIN PHARMACEUTICAL (BMRN) — Jan 31, 2008

BIOMARIN PHARMACEUTICAL INC
Date: Jan. 31, 2008 · CIK: 0001048477 · Accession: 0000000000-08-005409

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-26727

Date

January 31, 2008

Author

Jim Atkinson

Form

UPLOAD

Company

BIOMARIN PHARMACEUTICAL INC

Letter

Via Facsimile and U.S. Mail Mail Stop 6010 January 31, 2008 Mr. Jeffrey H. Cooper Chief Financial Officer BioMarin Pharmaceutical, Inc. 105 Digital Drive Novato, CA 94949 Re: BioMarin Pharmaceutical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2006 Form 10-Q for the quarterly p eriod ended September 30, 2007 File No. 000-26727

Dear Mr. Cooper: We have completed our review of your Form 10-K and related filings and have no further comments at this time. S i n c e r e l y , J i m A t k i n s o n Accounting Branch Chief

Show Raw Text

Via Facsimile and U.S. Mail Mail Stop 6010                                                                                                   January 31, 2008   Mr. Jeffrey H. Cooper Chief Financial Officer BioMarin Pharmaceutical, Inc. 105 Digital Drive Novato, CA  94949
Re: BioMarin Pharmaceutical, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2006 Form 10-Q for the quarterly p eriod ended September 30, 2007
 File No. 000-26727

Dear Mr. Cooper:
 We have completed our review of your Form 10-K and related filings and have no further
comments at this time.
       S i n c e r e l y ,
         J i m  A t k i n s o n         Accounting Branch Chief

SecProbe.io